Urogynecology, urinary and fecal incontinence

PubMed Free Full Text

Overactive bladder

Australia

• Australian Journal of General Practice
  • Overactive bladder syndrome: Management and treatment options [2020]

• Better Safer Care
  • Cystoscopy for uncomplicated overactive bladder symptoms

Austria

• Pharmacoepidemiology and Drug Safety
  • The role of prescription drugs in female overactive bladder syndrome—A population-wide cohort study [2020]

Austria, Germany, Switzerland

• Journal of Clinical Medicine
  • Perioperative Techniques for the Use of Botulinum Toxin in Overactive Bladder: Results of a Multinational Online Survey of Urogynecologists in Germany, Austria, and Switzerland [2023]

Brazil

• Advances in Therapy
  • Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System [2020]

• Revista da Associação Médica Brasileira
  • Overactive bladder - pharmacological treatment [2019]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • The Use of the Electromotive Drug Administration System in Patients with Overactive Bladder: A Review of the Clinical Effectiveness, Safety, and Cost-Effectiveness [2014]

• Canadian Urological Association
  • Canadian Urological Association guideline for the diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction [2019]
  • CUA guideline on adult overactive bladder [2017]

• Society of Obstetricians and Gynaecologists of Canada
  • Treatments for Overactive Bladder: Focus on Pharmacotherapy [2018]
  • Treatments for Overactive Bladder: Focus on Pharmacotherapy – An Addendum [2017]

China

• International Journal of Molecular Sciences
  • Evaluation and Management of Neurogenic Bladder: What Is New in China? [2015]

• PLoS ONE
  • Prevalence of overactive bladder in Chinese women: A systematic review and meta-analysis [2023]

Europe

• European Association of Urology
  • Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines? [2017]

France

• Progrès en Urologie
  • Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management: Translation of French recommendations [2014]

• Toxins
  • Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study [2023]

International

• Cochrane Database of Systematic Reviews
  • Bladder training for treating overactive bladder in adults [2023]

• Drugs & Aging
  • Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis [2020]

• European Urology Focus
  • Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials [2023]

• International Brazilian Journal of Urology
  • Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis [2023]

• Therapeutic Advances in Urology
  • Update on the management of overactive bladder [2021]

Middle East

• Advances in Therapy
  • The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey [2021]

Pakistan

• Pakistan Journal of Medical Sciences
  • Prevalence and associated risk factors among patients with overactive bladder syndrome in Pakistan [2021]

Poland

• Brain Sciences
  • Population-Based Study of Prevalence, Bother and Behavior Related to Treatment for Lower Urinary Tract Symptoms and Overactive Bladder among Polish Neurogenic Patients [2021]

• Ginekologia Polska
  • The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women [2021]

• Scientific Reports
  • Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study [2020]

Spain

• Archivos Españoles de Urología
  • Economic Impact Associated with Patients with Overactive Bladder on Drug Treatment with Mirabegron or Antimuscarinics in Spain [2023]

United Kingdom

• Journal of Clinical Urology
  • Botulinum toxin-A for the treatment of overactive bladder: UK contributions [2013]

• National Institute for Health and Care Excellence
  • Vibegron for treating symptoms of overactive bladder syndrome [2024]
  • Axonics sacral neuromodulation system for treating refractory overactive bladder [2020]
  • Mirabegron for treating symptoms of overactive bladder [2013]
  • Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome [2010]

• NHS England
  • Sacral Nerve Stimulation for Overactive Bladder [2015]

United States

• Advances in Therapy
  • Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review [2023]

• American Urogynecologic Society
  • Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder [2021]

• American Urological Association
  • The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder [2024]
  • Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019 [2019]
  • Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline [2012]

• International Urogynecology Journal
  • Assessing comprehension of online information in the United States for third-line treatment of overactive bladder [2023]

• JAMA Network Open
  • Inequities in Filled Overactive Bladder Medication Prescriptions in the US [2023]

• Journal of Comparative Effectiveness Research
  • Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective [2023]
  • Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review [2022]

{Related topics}

• Topic
  • Urinary incontinence